AZD9833

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Advanced ER-Positive HER2-Negative Breast Cancer

Drug Information

Target Indication

Advanced ER-Positive HER2-Negative Breast Cancer

Clinical Trial

Last updated: 2/26/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

AZNCF

ASTRAZENECA PLC

Related Pipeline

Generalized Anxiety Disorder

Metastatic Castration-resistant Prostate Cancer

Triple Negative Breast Neoplasms

Diabetes Mellitus, Type 2

Rheumatoid Arthritis